[CAS NO. 346688-38-8]  Pridopidine

Ships within Stock Price Qty Total
$0.00
$0.00
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [346688-38-8]

Catalog
HY-10684
Brand
MCE
CAS
346688-38-8

DESCRIPTION [346688-38-8]

Overview

MDLMFCD09835586
Molecular Weight281.41
Molecular FormulaC15H23NO2S
SMILESO=S(C1=CC(C2CCN(CCC)CC2)=CC=C1)(C)=O

For research use only. We do not sell to patients.

Summary

Pridopidine, a dopamine ( DA ) stabilizer, acts as a low affinity dopamine D2 receptor ( D2R ) antagonist. Pridopidine exerts high affinity towards sigma 1 receptor ( S1R ) with K i between 70 and 80 nM, which is ~100× higher than its affinity toward D2R.


IC50 & Target

Ki: 70-80 nM (sigma 1 receptor) [1]
Dopamine [1]
Dopamine D2 receptor [1]


In Vitro

Pridopidine, a dopamine (DA) stabilizer, Pridopidine may be a neuromodulatory agent with neuroprotective properties in Huntington disease (HD). To clarify the neuroprotective efficacy of Pridopidine and to explore the potential underling molecular mechanism, the ability of Pridopidine is evaluated to protect cells from apoptosis and to eventually activate pro-survival targets. Administration of Pridopidine (150 μM), the most effective dose, significantly reduces apoptosis in immortalized striatal knock-in cells expressing endogenous levels of mutant Htt (STHdh 111/111 ) and markedly enhances phosphorylation state of prosurvival kinase ERK [2] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.


In Vivo

Pridopidine is known to act as a low affinity D2R antagonist. Pridopidine’s activity may be attributed to binding the sigma 1 receptor (S1R), an endoplasmic reticulum (ER). To strengthen the hypothesis that the BDNF pathway is upregulated due to activation of the S1R, SD rats are treated with lower doses of Pridopidine (range 0.3-60 mg/kg), and analysed the expression of seven selected genes in the BDNF pathway by qPCR. Pridopidine doses of 3 and 15 mg/kg in rats occupy 57±2% and 85±2% of S1R, respectively, and both do not show occupancy of the D2R, as determined by in vivo PET imaging. The significant occupancy proportion of the D2R (44-66%) is observed only at a dose of 60 mg/kg. This PET study supports the conclusion that the upregulation of genes in rats treated with 15 mg/kg Pridopidine are a result of specific activation of the S1R. At 30 mg/kg, partial/low occupancy of the D2R is at levels of 22-33% (assuming linearity), and S1R is saturated. Indeed, qPCR analysis reveals that the upregulation of EGR1 (already up at 3 mg/kg), EGR2, HOMER1A, KLF5, and ARC expression are upregulated at the low 15 mg/kg dose and expression of CDNK1A and CEBPB are significantly upregulated from a low dose of 30 mg/kg (CEBPB is significantly increased at 3 mg/kg but not at 15 mg/kg) [1] . To further confirm the beneficial effect of Pridopidine on HD motor phenotype and to elucidate whether Pridopidine may act also as neuroprotective agent, preclinical studies in R6/2 mice have been undertaken. Daily administration of Pridopidine at a dose of 5 mg/kg, the most effective dose with no adverse effects, starting at the pre-symptomatic stage at 5 weeks for 6 weeks, significantly preserves motor function and prevents the progressive and dramatic motor worsening commonly observed in R6/2 mice. The beneficial effects of Pridopidine are maintained for about 4 weeks, after which mice show a slight worsening in performing both the horizontal ladder task and the open field. In addition, according to a Kaplan-Meier survival curve analysis, Pridopidine efficiently extends lifespan in the same mice [2] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.


Clinical Trial

NCT Number Sponsor Condition Start Date Phase
NCT00724048 Teva Branded Pharmaceutical Products R&D, Inc.
Huntington Disease
October 2008 Phase 2|Phase 3
NCT00665223 Teva Branded Pharmaceutical Products R&D, Inc.
Huntington´s Disease
April 2008 Phase 3
NCT04556656 Prilenia
Huntington Disease
October 16, 2020 Phase 3

Appearance

Solid


Shipping

Room temperature in continental US; may vary elsewhere.


Storage

Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL ( 355.35 mM ; Need ultrasonic)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 3.5535 mL 17.7677 mL 35.5353 mL
5 mM 0.7107 mL 3.5535 mL 7.1071 mL
10 mM 0.3554 mL 1.7768 mL 3.5535 mL
* Please refer to the solubility information to select the appropriate solvent.
In Vivo:
  • 1.

    Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

    Solubility: ≥ 2.5 mg/mL (8.88 mM); Clear solution

  • 2.

    Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.5 mg/mL (8.88 mM); Clear solution

  • 3.

    Add each solvent one by one: 10% DMSO >> 90% corn oil

    Solubility: ≥ 2.5 mg/mL (8.88 mM); Clear solution

* All of the co-solvents are available by MCE.


Synonyms

Piperidine, 4-[3-(methylsulfonyl)phenyl]-1-propyl-
4-[3-(Methylsulfonyl)phenyl]-1-propylpiperidine
ACR 16
ASP 2314
Pridopidine
FR 310826
Huntexil